Taken together, these findings suggest that targeting TNF-TNFR2 interaction with pharmacological agents, in an attempt to reduce the number and function of Tregs while enhancing the function and number of Teffs, could provide stronger immune responses against cancer cells and serve as a promising cancer therapeutic approach [55, 114]. The gene discussed is TNFRSF1B; the disease is cancer.